Bioventus (NASDAQ:BVS) Shares Down 8.2% – Here’s Why

by · The Cerbat Gem

Bioventus Inc. (NASDAQ:BVS – Get Free Report)’s stock price was down 8.2% on Friday . The company traded as low as $8.32 and last traded at $8.35. Approximately 154,082 shares were traded during trading, a decline of 43% from the average daily volume of 272,240 shares. The stock had previously closed at $9.10.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BVS shares. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a report on Wednesday. Weiss Ratings restated a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Barrington Research upgraded Bioventus to a “strong-buy” rating in a research report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Bioventus has an average rating of “Buy”.

Get Our Latest Stock Analysis on Bioventus

Bioventus Price Performance

The firm has a market cap of $693.53 million, a P/E ratio of 69.84 and a beta of 0.78. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.74 and a quick ratio of 1.14. The stock’s 50-day simple moving average is $8.10 and its two-hundred day simple moving average is $7.49.

Bioventus (NASDAQ:BVS – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.02. The firm had revenue of $157.90 million during the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%.

Bioventus Company Profile

(Get Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

Featured Stories